With a robust business strategy of strengthening its U.S. operations, India's Sun Pharmaceutical has emerged as the most valued Indian drug company. As stock markets hammered down valuations for other top Indian drug companies like Ranbaxy, Dr. Reddy's and Cipla, analysts have largely held Sun's valuations steady. In a rare interview with PharmAsia News' Indian bureau, Sun Pharmaceutical Chairman and Managing Director Dilip Shanghvi shares his thoughts on the long term goals for the company and speaks out on the tangle that his company is engaged in to acquire Israeli drug maker Taro.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.
Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.
Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.
